<article id="efficacy_CRVO_gains" class="slide" data-ag-name="Efficacy CRVO Gains">
  <div class="tab-title">CRVO</div>

  <h2 class="slide-title">RAPID AND SIGNIFICANT VISION <br>GAINS ACHIEVED VS. SHAM<sup class="footnote-link">1,4</sup><span class="asterisk">*</span></h2>
  <div class="chart">
    <div class="chart-desc">
      Mean change in BCVA as measured by ETDRS letter score from baseline at Week 24 (2ยบ endpoint)
    </div>
  <div class="chart-img"><img src="content_EN/img/charts_lg-crvo.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph, Boyer D, et al., 2012 and data on file.</span> <span>95% CI (17.4, 26.0); <i>p</i><0.0001*</span>
    </div>
    <div class="further-details one-line">
      <p><b>+21.7</b> letter difference </p>
        <span class="parallelogram"></span>
    </div>
  </div>
  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>A randomized, multicentre, double-masked, sham-controlled study in adult patients with macular edema secondary to CRVO. Patients were assigned randomly in a 3:2 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg (n=114) or sham (n=74) injections every 4 weeks for the 24 weeks (for a total of 6 injections).
    </p>
  </div>
  <div class="keys">
    <div class="chart-key">BCVA=best-corrected visual acuity; ETDRS=Early Treatment Diabetic Retinopathy Study.</div>
  </div>
</article>